Eupraxia Pharmaceuticals (NASDAQ: EPRX) has reported new endoscopic scoring data from its ongoing RESOLVE trial, reinforcing early clinical signals for EP-104GI in eosinophilic esophagitis. The findings highlight measurable improvements in disease severity metrics and support dose optimisation strategies ahead of Phase 2b readouts expected in late 2026, a critical milestone for the company’s clinical and financial trajectory.

Key Highlights

  • EREFS data indicates a 65% mean reduction in disease severity among patients receiving the highest injection protocol
  • Clinical response rates improved with greater esophageal coverage via increased injection count
  • Phase 1b/2a findings support 20-injection dosing strategy, now being tested in Phase 2b
  • Strong balance sheet with cash exceeding debt and a current ratio above 15, enabling trial continuity
  • Phase 2b top-line data expected in Q4 2026, representing a key valuation inflection point

RESOLVE Trial Data Signals Dose-Dependent Clinical Improvement

Eupraxia Pharmaceuticals (NASDAQ: EPRX) has reported new data from its Phase 1b/2a RESOLVE trial, focusing on the efficacy of EP-104GI in treating eosinophilic esophagitis (EoE), a chronic inflammatory condition of the esophagus. The data, presented at Digestive Disease Week in Chicago, centres on the Eosinophilic Esophagitis Endoscopic Reference Score (EREFS), a clinically validated tool used to assess disease severity.

Among patients receiving the highest treatment intensity—20 esophageal wall injections—the company reported a mean reduction in EREFS of 65% at week 12. This equates to a decline of 3.6 points from baseline, based on a subset of patients with initial scores above the clinically significant threshold of 2. The findings suggest a measurable reduction in both inflammatory and fibrotic manifestations of the disease.

EREFS Metrics Reinforce Therapeutic Signal in EoE

EREFS serves as a composite measure of disease activity, capturing key features such as edema, rings, exudates, furrows, and strictures. Patients without EoE typically exhibit scores near zero, while active disease is generally associated with scores above 2. Achieving a score of 2 or below is widely regarded as a meaningful clinical response.

In the RESOLVE trial, the proportion of patients reaching this response threshold increased with the number of injections administered. This dose-response relationship underscores the importance of esophageal surface coverage in delivering therapeutic benefit, a factor that differentiates EP-104GI’s delivery mechanism from systemic treatments.

The data also indicated consistent improvements across both inflammatory and fibrotic sub-scores, suggesting that EP-104GI may address multiple dimensions of disease pathology.

Trial Design and Progression Toward Phase 2b

The ongoing RESOLVE trial is structured as a multicentre, open-label, dose-escalation study evaluating safety, tolerability, pharmacokinetics, and efficacy. A total of 30 patients were enrolled in the Phase 1b/2a portion, with 83% presenting clinically significant EREFS scores at baseline.

Treatment was administered as a single dose via between 4 and 20 injections, with higher cohorts receiving increased dosing intensity and broader esophageal coverage. Patients were followed for up to 52 weeks in later cohorts, allowing for extended observation of durability and safety.

Building on these findings, Eupraxia has initiated the Phase 2b portion of the trial, a randomized, placebo-controlled study evaluating 120mg and 160mg dosing regimens. The selection of a 20-injection protocol for this phase reflects the clinical trends observed in earlier cohorts.

Balance Sheet Strength Supports Clinical Execution

Eupraxia Pharmaceuticals (NASDAQ: EPRX) maintains a capital structure that appears supportive of ongoing clinical development. The company holds more cash than debt and reports a current ratio of 15.12, indicating substantial short-term liquidity relative to liabilities.

This financial flexibility is particularly relevant given the capital-intensive nature of late-stage clinical trials. With Phase 2b recruitment underway and additional data disclosures planned, liquidity positioning will remain a key factor in execution risk and timeline adherence.

Recent upward revisions to earnings estimates by multiple analysts suggest improving sentiment around the company’s near-term outlook, although valuation metrics indicate the stock may be trading above intrinsic benchmarks based on current modelling frameworks.

Market Performance Reflects Clinical Momentum

Eupraxia’s equity performance has tracked its clinical progress over the past year. The stock has delivered an 85% return over the past 12 months and is up 31% over the last six months, reflecting increased investor attention to its EoE programme.

At a recent price of $7.42, the company’s market capitalisation stands at approximately $455 million. While recent gains indicate growing confidence in the EP-104GI platform, the sustainability of valuation will likely depend on the outcome of the Phase 2b trial and subsequent regulatory pathways.

Pipeline Positioning and Competitive Context in EoE Treatment

Eosinophilic esophagitis remains an area of unmet clinical need, with limited approved therapies and a growing patient population. Current treatment approaches include dietary management, proton pump inhibitors, and corticosteroids, each with varying degrees of efficacy and adherence challenges.

EP-104GI’s localized delivery approach, enabled by Eupraxia’s Diffusphere technology, is designed to optimise drug concentration at the site of inflammation while minimising systemic exposure. This mechanism may offer a differentiated profile if efficacy and safety are confirmed in larger, controlled studies.

However, the competitive landscape is evolving, with several biopharmaceutical companies advancing biologic therapies targeting underlying immune pathways. As such, differentiation will depend not only on clinical outcomes but also on durability, safety, and ease of administration.

Key Milestones and Execution Risks Ahead

The next major catalyst for Eupraxia Pharmaceuticals (NASDAQ: EPRX) is the release of top-line data from the Phase 2b portion of the RESOLVE trial, expected in the fourth quarter of 2026. This dataset will provide a more robust assessment of EP-104GI’s efficacy and safety in a controlled setting.

Execution risks include patient recruitment timelines, variability in clinical outcomes, and regulatory considerations. Additionally, as a clinical-stage biotechnology company, Eupraxia remains dependent on successful trial progression to generate long-term revenue streams.